| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,506 |
1,892 |
$114K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
711 |
508 |
$88K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,009 |
855 |
$37K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,014 |
742 |
$34K |
| 87631 |
|
605 |
428 |
$26K |
| 87428 |
|
578 |
507 |
$22K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
194 |
172 |
$12K |
| 87486 |
|
680 |
495 |
$11K |
| 87581 |
|
677 |
492 |
$11K |
| 87640 |
|
752 |
550 |
$10K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
43 |
41 |
$9K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
690 |
454 |
$7K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
53 |
48 |
$4K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
634 |
493 |
$4K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
46 |
40 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
66 |
59 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
35 |
34 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
73 |
71 |
$853.24 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
71 |
58 |
$736.24 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
56 |
43 |
$650.98 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
112 |
89 |
$465.27 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
22 |
19 |
$421.92 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
186 |
144 |
$180.84 |
| 81003 |
|
12 |
12 |
$18.46 |